Industry News
Pharmaceutical Industry News
As Bicara Therapeutics lines up…
As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer.
Colombians Are Fighting Over the Fate of Escobar’s Hippos
Colombia is facing pushback over its plan to cull wild hippos, which are descendants of the drug kingpin Pablo Escobar’s personal pets. The hippos, which are native to Africa, have threatened local wildlife and human
Supreme Court Continues Access to Abortion Pill by Mail, for a Few Days
Justice Samuel A. Alito Jr. has paused until at least Thursday a federal appeals court ruling against the Food and Drug Administration that would restrict access by mail to mifepristone.
CSL has slashed its revenue…
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma for $11.7 billion.
With the program’s seventh…
With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot.
Daiichi Sankyo aims to transform…
Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five
OVID Health has hired former…
OVID Health has hired former Edelman global public health lead Davide Scalenghe to expand the agency’s international strategy and partnerships work.
Flashy three-pointers; top…
Flashy three-pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a major athletic celebrity. Not for Eli
For Some Patients, Cancer Is Becoming Like a Chronic Illness
For some patients, cancer is becoming like a chronic illness.
The Abortion Pill Case Is a Disaster for Republicans
Making abortion illegal doesn’t stop abortions; it just stops safe ones. As the Supreme Court weighs a huge restriction on the abortion drug mifepristone, Molly Jong-Fast explains the three options the Supreme Court might take.
Hunting For Lexapro Clocks, Viagra Neckties and Other Vintage Pharmaceutical Merch
The days of giving pharmaceutical-branded swag to health care professionals are largely over. Now those items are hot on the thrifting scene.
Trump Plans to Fire F.D.A. Commissioner Marty Makary
Dr. Makary has been a supporter of the Make American Healthy Again Movement but made some enemies in the administration over vaping, the abortion pill and rejections of new drugs.
Eversana Intouch, the AI-powered…
Eversana Intouch, the AI-powered marketing agency arm of Eversana, pulled seasoned advertising exec Mike Guarino to serve as its new CEO.
During the weeklong stay by the…
During the weeklong stay by the Supreme Court to temporarily restore online access to the abortion pill mifepristone after a shock appeals court decision last Friday, scores of experts, industry heavyweights and former regulators have
About Half of Patients with Metastatic Lung Cancer Don’t Get Treatment, Study Finds
New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients?
Pharma launches are getting…
Pharma launches are getting riskier. Megan Driscoll explains why starting earlier—and thinking differently—makes the difference.
Strengthening core CDO values for…
Strengthening core CDO values for cell line development
Explore how targeted protein…
Explore how targeted protein degradation is reshaping drug discovery, enabling new approaches for difficult targets and advancing novel therapeutic modalities.
Gilead raised its previous…
Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a high-flying launch thus far.
With an FDA decision date looming…
With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a lawsuit against its U.S. commercial partner, NS Pharma, and its parent company, Nippon Shinyaku.